MHH Logo




ABACOPD is a randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in mild to moderate acute exacerbations of COPD.


Multicenter Study (Germany)

Approx. 25 centres



Chronic obstructive pulmonary disease (COPD)




The aim oh the clinical study is to demonstrate, that there is no relevant increase in the “failure-rate” for patients treated with placebo instead of antibiotic treatment both on top of standard of care. A patient is classified as an immediate treatment failure if additional antibiotic therapy is required during the treatment period or until the test of cure visit (primary endpoint).


Phase IV randomized double blind placebo-controlled multi-centre clinical trial



  • Adults older than 40 years of age
  • with a smoking history of 10 Pack Years or more
  • Diagnosed with COPD stages I-IV 
  • with mild to moderate acute exacerbation of COPD
  • defined by a sustained worsening of the patient’s condition (including at least 2 of the following symptoms: increased dyspnea, sputum production, and sputum purulence)
  • from the stable state and beyond normal day-to-day variations
  • necessitating a change in regular medication in a patient with underlying COPD
  • which the patient  can manage in his/her normal environment or with the help of additional medical assistance without need for intermediate or intensive care.